Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-Guérin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): KEYNOTE-676 cohort B.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Medical University of Vienna, NYU Langone Health, Detroit Medical Center, Michigan State University, University of Tsukuba, Merck & Co., Inc., Rahway, NJ, USA (United States), Carolina Urologic Research Center, Johns Hopkins University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4212913883